PROTEINLOGIC LIMITED

Their core work

ProteinLogic is a Cambridge-based biotech SME focused on protein biomarker diagnostics, particularly blood-based tests for infectious disease. Their flagship H2020 work validated a novel active tuberculosis diagnostic through a European multi-site clinical study, addressing a major global unmet need. They also contributed to personalised cancer susceptibility bioinformatics, positioning themselves at the intersection of molecular diagnostics, clinical validation, and precision medicine.

What they specialise in

How they've shifted over time

With only two projects both starting in 2015, there is no visible longitudinal shift within the H2020 dataset itself. Both engagements sit firmly in the health pillar, with a clear weighting toward diagnostics (TB) and bioinformatics-driven personalised medicine (cancer). Activity appears concentrated in the mid-2010s, with no new H2020 starts captured after 2015.

With no post-2015 H2020 starts visible, partners should verify current commercial status and pipeline before engaging on new consortia.

How they like to work

ProteinLogic has shown they can both lead and participate: they coordinated the larger ADVANTAGE clinical validation project while joining PanCanRisk as a contributing partner. With six unique partners across four countries from just two projects, their collaboration footprint is compact but pan-European. This pattern suggests a nimble SME capable of orchestrating focused clinical consortia rather than running large multi-thematic networks.

Six distinct partners across four European countries, built through one coordinated clinical validation project and one participation. The network is modest in size but international, reflecting the cross-border clinical sites typical of TB diagnostic studies.

What sets them apart

ProteinLogic stands out as a UK SME that won the SME Instrument Phase 2 and successfully coordinated a multi-million-euro, multi-country clinical validation of a TB diagnostic — a level of regulatory and clinical orchestration most small biotechs never reach. Their dual footprint in infectious disease diagnostics and cancer bioinformatics is unusual and suggests a core competency in translating protein biomarker science into validated clinical tests. For partners seeking an SME that can actually run an EU-funded clinical trial, not just supply reagents, they are a credible choice.

Highlights from their portfolio

• ADVANTAGE
  A EUR 3M SME-2 project they coordinated to clinically validate a novel active tuberculosis diagnostic across European sites — their largest and most strategically important project.
• PanCanRisk
  Personalised bioinformatics project for global cancer susceptibility, showing their expertise extends beyond infectious disease into oncology biomarkers.